Full Text View
Tabular View
No Study Results Posted
Related Studies
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
This study is ongoing, but not recruiting participants.
Study NCT00076713   Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First Received: February 2, 2004   Last Updated: March 19, 2008   History of Changes

February 2, 2004
March 19, 2008
April 2000
 
 
 
Complete list of historical versions of study NCT00076713 on ClinicalTrials.gov Archive Site
 
 
 
Antiphospholipid Syndrome Collaborative Registry (APSCORE)
Antiphospholipid Syndrome Collaborative Registry (APSCORE)

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.

The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.

The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.

 
Observational
Cohort, Prospective
Antiphospholipid Syndrome
 
 
Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003 Nov;48(11):3004-8. Review. No abstract available.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
2000
 
 

Inclusion Criteria:

  • Antiphospholipid antibodies with or without associated clinical manifestations
Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00076713
Robert A. S. Roubey, MD, University of North Carolina at Chapel Hill
NIAMS-099
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Center on Minority Health and Health Disparities (NCMHD)
 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP